Advertisement

Annals of Surgical Oncology

, Volume 20, Issue 9, pp 3044–3051 | Cite as

REG1A Expression Status Suggests Chemosensitivity Among Advanced Thoracic Esophageal Squamous Cell Carcinoma Patients Treated with Esophagectomy Followed by Adjuvant Chemotherapy

  • Yusuke Sato
  • Satoru Motoyama
  • Hiroshi Nanjo
  • Satoru Ito
  • Kei Yoshino
  • Tomohiko Sasaki
  • Kuniaki Kuribayashi
  • Yushi Nagaki
  • Kazuhiro Imai
  • Hajime Saito
  • Yoshihiro Minamiya
  • Jun-ichi Ogawa
Thoracic Oncology

Abstract

Background

Regenerating gene 1A (REG1A) plays an important role in tissue regeneration and in cell proliferation in the mucous membrane of the gastrointestinal tract. We previously reported that the positive expression status of REG1A was predictive of chemoradiosensitivity in patients treated with preoperative chemoradiotherapy before esophagectomy or with definitive chemoradiotherapy. To further confirm the utility of REG1A as a chemosensitivity marker, we carried out an additional retrospective clinical study aimed at determining whether REG1A is a reliable chemosensitivity marker in patients treated with esophagectomy followed by adjuvant chemotherapy.

Method

A total of 177 patients with T2–4 thoracic esophageal squamous cell carcinoma received curative surgery without preoperative treatment at Akita University Hospital between 2001 and 2011. A tissue microarray was constructed, and REG1A expression status was analyzed immunohistochemically. We then statistically analyzed the relationships between REG1A expression status and 5-year overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS).

Results

In the adjuvant group (n = 105), REG1A-positive patients showed significantly better prognoses than REG1A-negative patients. (5-year OS, p = .0022; DSS, p = .0004; and DFS, p = .0040). However, there were no significant differences between REG1A-positive and REG1A-negative patients in the surgery group (n = 72). Univariate and multivariate analyses showed REG1A expression status to be a significant prognostic factor affecting 5-year DSS, comparable to lymph node metastatic status.

Conclusion

The present study suggests REG1A expression status has the potential to be a highly reliable and clinically useful chemosensitivity marker in patients treated with advanced thoracic esophageal squamous cell carcinoma. REG1A expression status will provide a good indication of treatment strategy and enable more individualized treatment for patients.

Keywords

Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma Cell Esophageal Squamous Cell Carcinoma Patient Squamous Cell Carcinoma Patient Esophageal Squamous Cell Carcinoma Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

This study was supported by Takeda Science Foundation.

References

  1. 1.
    Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2002;232:225–32.CrossRefGoogle Scholar
  2. 2.
    Law S, Kwong D, Wong KF, Wong KH, Chu KM, Sham JS, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: Impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238:339–47.PubMedGoogle Scholar
  3. 3.
    Ando N, Iizuka T, Ide H, Ishida K, Shinoda M, Nishimaki T, et al. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21:4592–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81:684–90.PubMedCrossRefGoogle Scholar
  5. 5.
    Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.PubMedCrossRefGoogle Scholar
  6. 6.
    Sanuki N, Ishikura S, Shinoda M, Ito Y, Hayakawa K, Ando N. Radiotherapy quality assurance review for a multi-center randomized trial of locally advanced esophageal cancer: the Japan Clinical Oncology Group (JCOG) trial 0303. Int J Clin Oncol. 2012;17:105–11.PubMedCrossRefGoogle Scholar
  7. 7.
    Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y, et al. A novel gene activated in regenerating islets. J Biol Chem. 1988;263:2111–4.PubMedGoogle Scholar
  8. 8.
    Watanabe T, Yonekura H, Terazono K, Yamamoto H, Okamoto H. Complete nucleotide sequence of human reg gene and its expression in normal and tumoral tissues. The reg protein, pancreatic stone protein, and pancreatic thread protein are one and the same product of the gene. J Biol Chem. 1990;265:7432–9.PubMedGoogle Scholar
  9. 9.
    Miyaoka Y, Kadowaki Y, Ishihara S, Ose T, Fukuhara H, Kazumori H, et al. Transgenic overexpression of Reg protein caused gastric cell proliferation and differentiation along parietal cell and chief cell lineages. Oncogene. 2004;23:3572–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Unno M, Itoh T, Watanabe T, Miyashita H, Moriizumi S, Teraoka H, et al. Islet beta-cell regeneration and reg genes. Adv Exp Med Biol. 1992;321:61–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Sekikawa A, Fukui H, Fujii S, Ichikawa K, Tomita S, Imura J, et al. REG Ialpha protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells. Carcinogenesis. 2008;29:76–83.PubMedCrossRefGoogle Scholar
  12. 12.
    Yoshino N, Ishihara S, Rumi MA, Ortega-Cava CF, Yuki T, Kazumori H, et al. Interleukin-8 regulates expression of Reg protein in Helicobacter pylori-infected gastric mucosa. Am J Gastroenterol. 2005;100:2157–66.PubMedCrossRefGoogle Scholar
  13. 13.
    Astrosini C, Roeefzaad C, Dai YY, Dieckgraefe BK, Jöns T, Kemmner W. REG1A expression is a prognostic marker in colorectal cancer and associated with peritoneal carcinomatosis. Int J Cancer. 2008;123:409–13.PubMedCrossRefGoogle Scholar
  14. 14.
    Lee WS, Seo G, Shin HJ, Yun SH, Yun H, Choi N, et al. Identification of differentially expressed genes in microsatellite stable HNPCC and sporadic colon cancer. J Surg Res. 2008;144:29–35.PubMedCrossRefGoogle Scholar
  15. 15.
    Kimura N, Yonekura H, Okamoto H, Nagura H. Expression of human regenerating gene mRNA and its product in normal and neoplastic human pancreas. Cancer. 1992;70:1857–63.PubMedCrossRefGoogle Scholar
  16. 16.
    Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, et al. Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in human primary liver tumors with beta-catenin mutations. Oncogene. 2006;25:599–608.PubMedCrossRefGoogle Scholar
  17. 17.
    Minamiya Y, Kawai H, Saito H, Ito M, Hosono Y, Motoyama S, et al. REG1A expression is an independent factor predictive of poor prognosis in patients with non-small cell lung cancer. Lung Cancer. 2008;60:98–104.PubMedCrossRefGoogle Scholar
  18. 18.
    Sasaki Y, Minamiya Y, Takahashi N, Nakagawa T, Katayose Y, Ito A, et al. REG1A expression is an independent factor predictive of poor prognosis in patients with breast cancer. Ann Surg Oncol. 2008;15:3244–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Geng J, Fan J, Wang P, Fang ZJ, Xia GW, Jiang HW, et al. REG1A predicts recurrence in stage Ta/T1 bladder cancer. Eur J Surg Oncol. 2009;35:852–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Motoyama S, Sugiyama T, Ueno Y, Okamoto H, Takasawa S, Nanjo H, et al. REG I expression predicts long-term survival among locally advanced thoracic squamous cell esophageal cancer patients treated with neoadjuvant chemoradiotherapy followed by esophagectomy. Ann Surg Oncol. 2006;13:1724–31.PubMedCrossRefGoogle Scholar
  21. 21.
    Hayashi K, Motoyama S, Sugiyama T, Izumi J, Anbai A, Nanjo H, et al. REG Ialpha is a reliable marker of chemoradiosensitivity in squamous cell esophageal cancer patients. Ann Surg Oncol. 2008;15:1224–31.PubMedCrossRefGoogle Scholar
  22. 22.
    Hayashi K, Motoyama S, Koyota S, Koizumi Y, Wang J, Takasawa S, et al. REG I enhances chemo- and radiosensitivity in squamous cell esophageal cancer cells. Cancer Sci. 2008;99:2491–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Sato Y, Motoyama S, Maruyama K, Yoshino K, Sasaki T, Wakita A, et al. CMV reactivation caused by methylprednisolone therapy for ARDS after esophagectomy. Esophagus. 2012;9:141–6.CrossRefGoogle Scholar
  24. 24.
    Motoyama S, Saito R, Kitamura M, Ogawa J. Outcome of active surgery during intensive follow-up for second primary malignancy after esophagectomy for thoracic squamous cell esophageal carcinoma. J Am Coll Surg. 2003;197:914–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Sato Y, Motoyama S, Maruyama K, Okuyama M, Ogawa J, et al. A second malignancy is the major cause of death among thoracic squamous cell esophageal cancer patients negative for lymph node involvement. J Am Coll Surg. 2005;201:188–93.PubMedCrossRefGoogle Scholar
  26. 26.
    Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008;26:5630–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Köchli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249–56.PubMedCrossRefGoogle Scholar
  29. 29.
    Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–83.PubMedCrossRefGoogle Scholar
  30. 30.
    Miyata H, Doki Y, Shinozaki H, Inoue M, Yano M, Fujiwara Y, et al. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res. 2000;6:4859–65.PubMedGoogle Scholar
  31. 31.
    Takasawa S, Ikeda T, Akiyama T, Nata K, Nakagawa K, Shervani NJ, et al. CyclinD1 activation through ATF-2 in Reg-induced pancreatic b-cell regeneration. FEBS Lett. 2006;580:585–91.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Yusuke Sato
    • 1
  • Satoru Motoyama
    • 1
  • Hiroshi Nanjo
    • 2
  • Satoru Ito
    • 2
  • Kei Yoshino
    • 1
  • Tomohiko Sasaki
    • 1
  • Kuniaki Kuribayashi
    • 1
  • Yushi Nagaki
    • 1
  • Kazuhiro Imai
    • 1
  • Hajime Saito
    • 1
  • Yoshihiro Minamiya
    • 1
  • Jun-ichi Ogawa
    • 1
  1. 1.Department of SurgeryAkita University Graduate School of MedicineAkitaJapan
  2. 2.Department of PathologyAkita University Graduate School of MedicineAkitaJapan

Personalised recommendations